Moderate to severe plaque psoriasis in patients ≥6 yr who are candidates for systemic therapy or phototherapy. Alone or in combination w/ MTX for active psoriatic arthritis in adults when previous DMARDs therapy has been inadequate. Active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Active non-radiographic axial spondyloarthritis (nr-axSpA) w/ objective signs of inflammation as indicated by elevated C-reactive protein (CRP) &/or MRI evidence in adults who responded inadequately to NSAIDs.
Discontinue use if anaphylactic or other serious allergic reaction occurs. Not to be given in active TB patients. Patients w/ chronic or history of recurrent infection; active inflammatory bowel disease (eg, Crohn's disease & ulcerative colitis). Latex-sensitive individuals. Not to be given concurrently w/ live vaccines. Pregnancy & lactation. Ped <18 yr; ped w/ plaque psoriasis <6 yr.
Sign Out
 150 mg_mL17f0b3bc-b13a-44ad-a851-a61801205dd7.GIF)
